

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
EXTENSION OF TIME FOR APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTOR**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) is pleased to announce that Mr. HSU Dong An (“**Mr. HSU**”) has been appointed as an independent non-executive Director of the Company, the chairperson of the nomination committee and a member of the audit committee (the “**Audit Committee**”), the remuneration committee and the nomination committee of the Company (the “**Nomination Committee**”) with effect from 15 August 2023.

Mr. HSU Dong An, aged 34, has been a director of a subsidiary of a listed Company in Hong Kong since July 2021. He has over 11 years of experience in the field of corporate finance, financial management and audit experience in Hong Kong and the People’s Republic of China. From April 2013 to June 2021, Mr. HSU was a vice president of corporate finance of a previously listed Company in Hong Kong. Mr. HSU is a CFA charterholder of the CFA Institute. He graduated from the University of Southern California with a bachelor’s degree in Accounting in 2011.

Mr. HSU has not entered into any service contract for his duties as the independent non-executive Director with the Company. He will be entitled to receive an annual director’s fee of HK\$60,000 which was determined by the Board based on recommendation of the

remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. HSU (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on GEM ("GEM") of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules")) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to the appointment of Mr. HSU is needed to be brought to the attention of the shareholders of the Company.

Mr. HSU has confirmed that he meets the independence criteria as set out in Rule 5.09 of the GEM Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. HSU for joining the Company.

Following the appointment of Mr. HSU with effect from 15 August 2023 and the resignation of Mr. LAM Kit Sun ("Mr. LAM") and Dr. LIU Ta-pei ("Dr. LIU") as disclosed in the announcements of the Company dated 16 May 2023 and 3 August 2023, the Company only has two INEDs and there is a vacancy in the position of the INED, the member of the Audit Committee and the Nomination Committee respectively. Thus, the number of the INEDs falls below (i) the minimum number of three INEDs required under Rule 5.05(1) of the GEM Listing Rules; and (ii) the minimum number of three members of the audit committee required under Rule 5.28 of the GEM Listing Rules. The Company fails to meet the requirement that the nomination committee must be comprising a majority of independent non-executive directors under Rule 5.36A of the GEM Listing Rules.

Pursuant to Rules 5.06(1) and 5.33 of the GEM Listing Rules, the Company should appoint sufficient number of independent non-executive directors and make appropriate appointment to the audit committee within three months after failing to meet the requirements under Rules 5.05(1) and 5.28 of the GEM Listing Rules (i.e. on or before 15 August 2023).

EXTENSION OF TIME FOR APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

During the past months, the Company has been actively identifying and approaching potential candidates to fill the vacancies in the Board and its committees occasioned by the resignation of Mr. LAM and Dr. LIU. As the Company requires more time to identify the second suitable candidate of the independent non-executive Director, an application has been made by the Company to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for, and the Stock Exchange has granted, a waiver from strict compliance with Rules 5.05(1), 5.06, 5.28, 5.33 and 5.36A of the GEM Listing Rules and an extension of time for a period of one month from 15 August 2023 to 15 September 2023 for filling the vacancies.

The Company will make its best endeavours to appoint an independent non-executive Director and fill the relevant vacancies so as to comply with the relevant requirements of the GEM Listing Rules as soon as practicable. The Company will make further announcement as and when appropriate.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 15 August 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence and Mr. HSU Dong An as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at <https://www.hkgem.com> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.